Complete blood count differences in a cohort of Down syndrome neonates with transient abnormal myelopoiesis screened for GATA1 pathogenic variants.

American Journal of Medical Genetics. Part a
Mireya Orozco-VelaJorge Román Corona-Rivera

Abstract

Transient abnormal myelopoiesis (TAM) raises the risk for acute myeloid leukemia of Down syndrome (DS) (ML-DS), and both are related to GATA1 pathogenic variants. Here, we analyzed which findings on complete blood count (CBC) are associated with TAM in a cohort of neonates with DS screened for GATA1 pathogenic variants. The CBCs were compared among 70 newborns with DS, including 16 patients (22.9%) with TAM (cases), and 54 patients (77.1%) without TAM (controls). TAM was defined as peripheral circulating blasts (PCBs) ≥ 1%. PCR and direct sequencing were used to screen DNA samples from peripheral blood for GATA1 exon 2 mutations. Multivariate logistic regression analyses determined that the mean count of lymphocytes was significantly higher in DS infants with TAM (p = .035) and that lymphocytosis confers a risk for TAM (adjusted odds ratio = 7.23, 95% confidence intervals: 2.02-25.92). Pathogenic variants of GATA1 were identified in 2 of 70 analyzed DS neonates (2.9%), of which one had ML-DS and another had an asymptomatic TAM. Among those DS infants with TAM, the GATA1 pathogenic variant detection was 12.5%. Our results indicated that lymphocytosis is associated with TAM in neonates with DS. However, since not all infants with...Continue Reading

References

Feb 1, 1997·Seminars in Perinatology·A ZipurskyJ Doyle
Dec 6, 2003·Blood·Momin AhmedParesh Vyas
Nov 24, 2004·Pediatric Blood & Cancer·Gita V Massey
Jun 23, 2011·International Journal of Laboratory Hematology·D-W KimD-W Ryang
Jul 1, 2011·Blood·Kate A AlfordUNKNOWN International Myeloid Leukemia-Down Syndrome Study Group
Jul 27, 2011·Pediatrics·Marilyn J Bull, UNKNOWN Committee on Genetics
Aug 3, 2011·American Journal of Perinatology·Gregory L JacksonWilliam D Engle
May 2, 2012·Pediatrics·Richard A Polin, UNKNOWN Committee on Fetus and Newborn
Nov 14, 2013·Genetics and Molecular Research : GMR·L B QueirozI Ferrari
Aug 8, 2015·Clinics in Perinatology·Erick Henry, Robert D Christensen
Feb 9, 2017·American Journal of Medical Genetics. Part a·Francisco Javier Martínez-MacíasJorge Román Corona-Rivera
Jun 20, 2018·British Journal of Haematology·Oliver TunstallUNKNOWN British Society for Haematology
Dec 30, 2018·Pediatrics International : Official Journal of the Japan Pediatric Society·Kenichiro Watanabe

❮ Previous
Next ❯

Citations

Jan 5, 2021·International Journal of Hematology·Genki YamatoYasuhide Hayashi
Aug 28, 2021·Cancers·Carini Picardi Morais de CastroSergi Cuartero

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.